Cardiovascular Effects of Home Dialysis Therapies: A Scientific Statement From the American Heart Association CIRCULATION Sarnak, M. J., Auguste, B. L., Brown, E., Chang, A. R., Chertow, G. M., Hannan, M., Herzog, C. A., Nadeau-Fredette, A., Tang, W., Wang, A., Weiner, D. E., Chan, C. T., Amer Heart Assoc Council Kidney Ca, Council Arteriosclerosis Thrombosi, Council Cardiovasc Radiology Inter, Council Clinical Cardiology, Council Hypertension, Council Lifestyle Cardiometab Hlth 2022; 146 (11): E146-E164

Abstract

Cardiovascular disease is the leading cause of morbidity and mortality in patients with end-stage kidney disease. Currently, thrice-weekly in-center hemodialysis for 3 to 5 hours per session is the most common therapy worldwide for patients with treated kidney failure. Outcomes with thrice-weekly in-center hemodialysis are poor. Emerging evidence supports the overarching hypothesis that a more physiological approach to administering dialysis therapy, including in the home through home hemodialysis or peritoneal dialysis, may lead to improvement in several cardiovascular risk factors and cardiovascular outcomes compared with thrice-weekly in-center hemodialysis. The Advancing American Kidney Health Initiative, which has a goal of increasing the use of home dialysis, is aligned with the American Heart Association's 2024 mission to champion a full and healthy life and health equity. We conclude that incorporation of interdisciplinary care models to increase the use of home dialysis therapies in an equitable manner will contribute to the ultimate goal of improving outcomes for patients with kidney failure and cardiovascular disease.

View details for DOI 10.1161/CIR.0000000000001088

View details for Web of Science ID 000853194300003

View details for PubMedID 35968722